Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

CABL001i12201 (CML)

Clinical study to determine the dose and safety of asciminib in children and adolescents with chronic myeloid leukemia in the chronic phase.
Who can enter
  • Children with chronic myeloid leukemia in the chronic phase, previously treated with one or more tyrosine kinase inhibitors
  • Age: between 1 and 18 years old


The goal of this study is to study how safe asciminib is in children and adolescents and how well it works.


Chronic myeloid leukemia is a form of bloodcancer. It can be treated with several drugs, one of which is asciminib. Asciminib has until now only been tested in adult patients with CML, and is used in a tablet with 40 mg. We expect children might need smaller tablets. We want to use this study to find the dose needed for children, and to see if that dose needs to change with weight.

 Two different tablets are used in this study, firstly the ‘adult’ tablet of 40 mg, but also a mini-tablet of 1 mg. In two different parts both tablets will be tested. A participant will only take 1 type of tablet, either the 40 mg tablet or the 1 mg mini-tablet.

In order to participate in a study please refer to your/your child’s doctor.
For international patients: please feel welcome to contact our International Office.

Last reviewed

May 26, 2023